Compare GSK plc (GSK) vs Keysight Technologies Inc (KEYS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GSK plc vs Keysight Technologies Inc — how do they compare? GSK plc trades at $52.46 (market cap $101.34B), while Keysight Technologies Inc trades at $317.54 (market cap $55.15B). The key difference: GSK plc is the larger of the two by market cap, and GSK plc pays a 3.49% dividend while Keysight Technologies Inc pays none. Which is the better fit depends on your goals.
| GSK | KEYS | |
|---|---|---|
Market Cap | $101.34B | $55.15B |
Sector | Health | Technology |
52-Week High | $61.18 | $373.34 |
52-Week Low | $36.20 | $158.51 |
Enterprise Value | $121.95B | $55.50B |
Dividend Yield | 3.49% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GSK's stock trades at $51.25, down 1.99% on the day, with a bearish technical signal from moving averages. Fundamentally, the company shows strong profitability with a 17.78% net margin and 36.42% ROE, supported by a consistent earnings beat history. Recent positive clinical trial results for Jemperli in rectal cancer and FDA approval for Utebzi highlight pipeline progress. Valuation appears reasonable with a P/E of 13.71 and EV/EBITDA of 9.16.
The outlook balances a solid core business and promising oncology pipeline against a mixed analyst consensus and near-term cash flow pressures. Key opportunities lie in execution of new drug launches and the upcoming CEO strategy update, while risks include clinical trial setbacks, competitive pressures, and integration of potential acquisitions like Nuvalent.
Keysight Technologies (KEYS) trades at $325.73, up 1.53% today, with a neutral technical signal and bullish moving averages. The company reported strong earnings beats in recent quarters, with Q1 2026 EPS of $2.87 exceeding the $2.32 estimate. Revenue for 2025 was $5.38 billion, with a net income margin of 15.81%. Recent news highlights expansion in 5G, cybersecurity testing, and photonics design automation through acquisitions and partnerships.
The outlook is positive, supported by analyst consensus with an 81.25% buy rating and a $396.56 price target, implying 22% upside. Risks include high valuation multiples, such as a P/E of 51.97, and volatile cash flow trends, with net cash flow turning negative in 2026. Growth drivers include AI-driven data center demand and 5G network expansion, but execution on investments remains key.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About GSK plc
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →About Keysight Technologies Inc
Keysight Technologies is a leader in the field of testing and measurement, helping electronics OEMs and suppliers alike bring products to market to fit industry standards and specifications. Keysight specializes in the communications market, but also supplies into the government, automotive, industrial, and semiconductor manufacturing markets. Keysight's solutions include testing tools, analytical software, and services. The firm's stated objective is to reduce time to market and improve efficiency at its more than 30,000 customers.
Read more on KEYS →
